A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans

References

• Jerez Puebla LE. Fungal infections in immunosuppressed patients. Immunodeficiency. 2012. doi:10.5772/51512
   Google Scholar
• Rodrigues ML, Nosanchuk JD, Reynolds TB. Fungal diseases as neglected pathogens: a wake-up call to public health officials. PLoS Negl Trop Dis. 2020;14(2):1–9. doi:10.1371/journal.pntd.0007964
   Web of Science ®Google Scholar
• Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep. 2011;3(1):1–8. doi:10.3410/M3-14
   Google Scholar
• Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017;3(4):57. doi:10.3390/jof3040057
   Web of Science ®Google Scholar
• Hurley R, De Louvois J. Candida vaginitis. Postgrad Med J. 1979;55:645–647. doi:10.1136/pgmj.55.647.645
   PubMed Web of Science ®Google Scholar
• Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Physician. 2001;63(4):697–702. doi:10.1056/nejmp048152
   Web of Science ®Google Scholar
• Paladine HL, Desai UA. Vaginitis: diagnosis and treatment. Am Acad Fam Physicians. 2018;97(5):321–329.
   PubMed Web of Science ®Google Scholar
• Sobel JD. Vulvovaginal candidiasis. Lancet. 2007;369(9577):1961–1971. doi:10.1016/S0140-6736(07)60917-9
   PubMed Web of Science ®Google Scholar
• Musa K, Ahmed M, Shahpudin S, et al. Resistance of Candida glabrata to drugs and the host immune system. Clin Microbiol Infect Dis. 2018;3(3):1–4. doi:10.15761/cmid.1000145
   Google Scholar
• Bhattacharjee P. Epidemiology and antifungal susceptibility of Candida species in a tertiary care hospital, Kolkata, India. Curr Med Mycol. 2016;2(2):20–27. doi:10.18869/acadpub.cmm.2.2.5
   Google Scholar
• Gullo A. Invasive fungal infections. The challenge continues. Drugs. 2009;69(1):65–73. doi:10.2165/11315530-000000000-00000
   Web of Science ®Google Scholar
• Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–140. doi:10.1093/cid/ciw691
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–1732. doi:10.1093/cid/cit136
   PubMed Web of Science ®Google Scholar
• Rodriguez L, Bustamante B, Huaroto L, et al. A multi-centric study of Candida bloodstream infection in Lima-Callao, Peru: species distribution, antifungal resistance and clinical outcomes. PLoS One. 2017;12(4):1–12. doi:10.1371/journal.pone.0175172
   Web of Science ®Google Scholar
• Maheronnaghsh M, Fatahinia M, Dehghan P, Teimoori A. Identification of Candida species and antifungal susceptibility in cancer patients with oral lesions in Ahvaz, Southern West of Iran. Adv Biomed Res. 2020;9(1):50. doi:10.4103/abr.abr_214_19
   Google Scholar
• Perfect JR. Is there an emerging need for new antifungals? Expert Opin Emerg Drugs. 2016;21(2):129–131. doi:10.1517/14728214.2016.1155554
   PubMed Web of Science ®Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12(1):40–79. doi:10.1128/cmr.12.1.40
   PubMed Web of Science ®Google Scholar
• The fungus among us: an antifungal review. https://uspharmacist.com/article/the-fungus-among-us-an-antifungal-review. Accessed October 16, 2021.
   Google Scholar
• Scheinfeld N. Ketoconazole: a review of a workhorse antifungal molecule with a focus on new foam and gel formulations. Drugs Today. 2008;44(5):369–380. doi:10.1358/DOT.2008.44.5.1216598
   PubMed Web of Science ®Google Scholar
• McKeny PT, Nessel TA, Zito PM. Antifungal Antibiotics. StatPearls; 2021.
   Google Scholar
• Ahmad A, Khan A, Manzoor N, Khan LA. Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida. Microb Pathog. 2010;48(1):35–41. doi:10.1016/j.micpath.2009.10.001
   PubMed Web of Science ®Google Scholar
• Autmizguine J, Smith PB, Prather K, et al. Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. J Antimicrob Chemother. 2018;73(12):3482–3487. doi:10.1093/jac/dky353
   PubMed Web of Science ®Google Scholar
• Gong Y, Liu W, Huang X, Hao L, Li Y, Sun S. Antifungal activity and potential mechanism of n-butylphthalide alone and in combination with fluconazole against Candida albicans. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.01461
   Web of Science ®Google Scholar
• Rybak JM, Muñoz JF, Barker KS, et al. Mutations in TAC1B: a novel genetic determinant of clinical fluconazole resistance in Candida auris. mBio. 2020;11(3):1–16. doi:10.1128/mBio.00365-20
   Web of Science ®Google Scholar
• Warrilow AGS, Melo N, Martel CM, et al. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-α demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother. 2010;54(10):4225–4234. doi:10.1128/AAC.00316-10
   Web of Science ®Google Scholar
• Warrilow AGS, Mullins JGL, Hull CM, et al. S279 point mutations in Candida albicans sterol 14-α demethylase (CYP51) reduce in vitro inhibition by fluconazole. Antimicrob Agents Chemother. 2012;56(4):2099–2107. doi:10.1128/AAC.05389-11
   Web of Science ®Google Scholar
• Flowers SA, Colón B, Whaley SG, Schuler MA, David Rogers P. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother. 2015;59(1):450–460. doi:10.1128/AAC.03470-14
   PubMed Web of Science ®Google Scholar
• De Petris A, Crestoni ME, Pirolli A, et al. Binding of azole drugs to heme: a combined MS/MS and computational approach. Polyhedron. 2015;90:245–251. doi:10.1016/j.poly.2015.02.011
   Web of Science ®Google Scholar
• Balding PR, Porro CS, McLean KJ, et al. How do azoles inhibit cytochrome P450 enzymes? A density functional study. J Phys Chem A. 2008;112(50):12911–12918. doi:10.1021/jp802087w
   Web of Science ®Google Scholar
• Warrilow AG, Parker JE, Kelly DE, Kelly SL. Azole affinity of sterol 14-demethylase (CYP51) enzymes from Candida albicans and homo sapiens. Antimicrob Agents Chemother. 2013;57(3):1352–1360. doi:10.1128/AAC.02067-12
   PubMed Web of Science ®Google Scholar
• Xiang MJ, Liu JY, Ni PH, et al. Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 2013;13(4):386–393. doi:10.1111/1567-1364.12042
   PubMed Web of Science ®Google Scholar
• Marichal P, Vanden Bossche H, Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1997;41(10):2229–2237. doi:10.1128/aac.41.10.2229
   Web of Science ®Google Scholar
• Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology. 1999;145(10):2701–2713. doi:10.1099/00221287-145-10-2701
   Web of Science ®Google Scholar
• Kumar A, Nair R, Kumar M, et al. Assessment of antifungal resistance and associated molecular mechanism in Candida albicans isolates from different cohorts of patients in North Indian state of Haryana. Folia Microbiol (Praha). 2020;65(4):747–754. doi:10.1007/s12223-020-00785-6
   Web of Science ®Google Scholar
• Njunda AL, Nsagha DS, Assob JCN, Kamga HL, Teyim P. In vitro antifungal susceptibility patterns of Candida albicans from HIV and aids patients attending the Nylon Health District hospital in Douala, Cameroon. J Public Health Africa. 2012;3(1):4–7. doi:10.4081/jphia.2012.e2
   Google Scholar
• Bhargava A, Dakwala F, Saigal S, Mehra S. Identification of Candida albicans by using different culture medias and its association in potentially malignant and malignant lesions. Contemp Clin Dent. 2011;2(3):188. doi:10.4103/0976-237x.86454
   Google Scholar
• Matare T, Nziramasanga P, Gwanzura L, Robertson V. Experimental germ tube induction in Candida albicans: an evaluation of the effect of sodium bicarbonate on morphogenesis and comparison with pooled human serum. Biomed Res Int. 2017;2017:8–13. doi:10.1155/2017/1976273
   Web of Science ®Google Scholar
• Munin E, Giroldo LM, Alves LP, Costa MS. Study of germ tube formation by Candida albicans after photodynamic antimicrobial chemotherapy (PACT). J Photochem Photobiol B. 2007;88(1):16–20. doi:10.1016/j.jphotobiol.2007.04.011
   Web of Science ®Google Scholar
• Torosantucci A, Romagnoli G, Chiani P, et al. Candida albicans yeast and germ tube forms interfere differently with human monocyte differentiation into dendritic cells: a novel dimorphism-dependent mechanism to escape the host’s immune response. Infect Immun. 2004;72(2):833–843. doi:10.1128/IAI.72.2.833-843.2004
   Web of Science ®Google Scholar
• Houang ETS, Chu KC, Koehler AP, Cheng AFB. Use of CHROMagar Candida for genital specimens in the diagnostic laboratory. J Clin Pathol. 1997;50(7):563–565. doi:10.1136/jcp.50.7.563
   Web of Science ®Google Scholar
• Willinger B, Hillowoth C, Selitsch B, Manafi M. Performance of Candida ID, a new chromogenic medium for presumptive identification of Candida species, in comparison to CHROMagar Candida. J Clin Microbiol. 2001;39(10):3793–3795. doi:10.1128/JCM.39.10.3793-3795.2001
   Web of Science ®Google Scholar
• Merlino J, Tambosis E, Veal D. Chromogenic tube test for presumptive identification or confirmation of isolates as Candida albicans. J Clin Microbiol. 1998;36(4):1157–1159. doi:10.1128/jcm.36.4.1157-1159.1998
   Web of Science ®Google Scholar
• Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol. 1994;32(8):1923–1929. doi:10.1128/jcm.32.8.1923-1929.1994
   PubMed Web of Science ®Google Scholar
• Lahoylahoy LD, Mendoza BC. Evaluation of CHROMagar Candida in the rapid identification of medically important species of Candida. Int J Biosci. 2017;11(1):380–385. doi:10.12692/ijb/11.1.380-385
   Google Scholar
• Sharma P, Sambyal S, Shrivastava D. Evaluation of Candida species from clinical specimens by using chromagar. Int J Adv Res. 2017;5(2):1750–1755. doi:10.21474/ijar01/3337
   Google Scholar
• Mathavi S, Sasikala G, Kavitha A, Priyadarsini RI. CHROMagar as a primary isolation medium for rapid identification of Candida and its role in mixed Candida infection in sputum samples. Indian J Microbiol Res. 2016;3(2):141. doi:10.5958/2394-5478.2016.00033.9
   Google Scholar
• Faraz A, Ghaffar UB, Tahir Ansari WS. Evaluation of diagnostic efficacy of chromagar Candida for differentiation: Taylor’s libraries. ISRA Med J. 2016;8(4):5.
   Google Scholar
• Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol. 1996;34(9):2154–2157. doi:10.1128/jcm.34.9.2154-2157.1996
   Web of Science ®Google Scholar
• Yücesoy M, Şentürker Güldaş N, Yuluǧ N. Disk diffusion method for fluconazole susceptibility testing of Candida albicans strains. J Chemother. 2001;13(2):161–166. doi:10.1179/joc.2001.13.2.161
   PubMed Web of Science ®Google Scholar
• Kiraz N, Dag I, Oz Y, Yamac M, Kiremitci A, Kasifoglu N. Correlation between broth microdilution and disk diffusion methods for antifungal susceptibility testing of caspofungin, voriconazole, amphotericin B, itraconazole and fluconazole against Candida glabrata. J Microbiol Methods. 2010;82(2):136–140. doi:10.1016/j.mimet.2010.05.002
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Vol. 28. 3rd. Wayne P, ed. Clinical and Laboratory Standards Institute; CLSI Document M27-A3. 2008.
   Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th. Wayne P, ed. Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• Alyousef AA. Antifungal activity and mechanism of action of different parts of Myrtus communis growing in Saudi Arabia against. J Nanomater. 2021;2021. doi:10.1155/2021/3484125
   Web of Science ®Google Scholar
• Pam VK, Akpan JU, Oduyebo OO, et al. Fluconazole susceptibility and ERG11 gene expression in vaginal Candida species isolated from Lagos Nigeria. Int J Mol Epidemiol Genet. 2012;3(1):84–90.
   PubMedGoogle Scholar
• Alastruey-Izquierdo A, Cuenca-Estrella M. EUCAST and CLSI: how to assess in vitro susceptibility and clinical resistance. Curr Fungal Infect Rep. 2012;6(3):229–234. doi:10.1007/s12281-012-0100-3
   Google Scholar
• Cuesta I, Bielza C, Cuenca-Estrella M, Larrañaga P, Rodríguez-Tudela JL. Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrob Agents Chemother. 2010;54(4):1541–1546. doi:10.1128/AAC.01688-09
   Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19(2):435–447. doi:10.1128/CMR.19.2.435-447.2006
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 1997;24(2):235–249. doi:10.1093/clinids/24.2.235
   PubMed Web of Science ®Google Scholar
• Ortiz B, Pérez-Alemán E, Galo C, Fontecha G. Molecular identification of Candida species from urinary infections in Honduras. Rev Iberoam Micol. 2018;35(2):73–77. doi:10.1016/j.riam.2017.07.003
   Web of Science ®Google Scholar
• Erazo BM, Ramírez GA, Cerrato LE, et al. Prevalence of Hb S (HHB: c.20A>T) in a Honduran population of African descent. Hemoglobin. 2015;39(2):134–137. doi:10.3109/03630269.2015.1012294
   PubMed Web of Science ®Google Scholar
• Sayers EW, Beck J, Brister JR, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2020;48(D1):D9–D16. doi:10.1093/nar/gkz899
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242. doi:10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Hargrove TY, Friggeri L, Wawrzak Z, et al. Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J Biol Chem. 2017;292(16):6728–6743. doi:10.1074/jbc.M117.778308
   PubMed Web of Science ®Google Scholar
• Sagatova AA, Keniya MV, Wilson RK, Monk BC, Tyndall JDA. Structural insights into binding of the antifungal drug fluconazole to Saccharomyces cerevisiae lanosterol 14α-demethylase. Antimicrob Agents Chemother. 2015;59(8):4982–4989. doi:10.1128/AAC.00925-15
   PubMed Web of Science ®Google Scholar
• Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein sequences. Protein Sci. 2018;27(1):135–145. doi:10.1002/pro.3290
   PubMed Web of Science ®Google Scholar
• Faure G, Joseph AP, Craveur P, et al. IPBAvizu: a PyMOL plugin for an efficient 3D protein structure superimposition approach. Source Code Biol Med. 2019;14(1):1–5. doi:10.1186/s13029-019-0075-3
   Web of Science ®Google Scholar
• Adasme MF, Linnemann KL, Bolz SN, et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49(W1):W530–W534. doi:10.1093/nar/gkab294
   PubMed Web of Science ®Google Scholar
• Berendsen HJC, van der Spoel D, van Drunen R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun. 1995;91(1–3):43–56. doi:10.1016/0010-4655(95)00042-E
   Web of Science ®Google Scholar
• Abraham MJ, Murtola T, Schulz R, et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1–2:19–25. doi:10.1016/j.softx.2015.06.001
   Google Scholar
• Geneious Prime. Geneious all rights reserved. molecular biology and sequence analysis software. Available from: https://www.geneious.com/prime/. Accessed November 22, 2021.
   Google Scholar
• Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–1874. doi:10.1093/molbev/msw054
   PubMed Web of Science ®Google Scholar
• Zhang J, Li L, Lv Q, Yan L, Wang Y, Jiang Y. The fungal CYP51s: their functions, structures, related drug resistance, and inhibitors. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.00691
   Web of Science ®Google Scholar
• Liu M, Zheng N, Li D, et al. Cyp51A-based mechanism of azole resistance in Aspergillus fumigatus: illustration by a new 3D Structural Model of Aspergillus fumigatus CYP51A protein. Med Mycol. 2016;54(4):400–408. doi:10.1093/mmy/myv102
   Web of Science ®Google Scholar
• Sagatova AA, Keniya MV, Wilson RK, Sabherwal M, Tyndall JDA, Monk BC. Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14α-demethylase. Sci Rep. 2016;6:1–11. doi:10.1038/srep26213
   Web of Science ®Google Scholar
• Parker JE, Warrilow AGS, Price CL, Mullins JGL, Kelly DE, Kelly SL. Resistance to antifungals that target CYP51. J Chem Biol. 2014;7(4):143–161. doi:10.1007/s12154-014-0121-1
   PubMedGoogle Scholar
• Becher R, Wirsel SGR. Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens. Appl Microbiol Biotechnol. 2012;95(4):825–840. doi:10.1007/s00253-012-4195-9
   PubMed Web of Science ®Google Scholar
• Lamb DC, Kelly DE, Schunck WH, et al. The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem. 1997;272(9):5682–5688. doi:10.1074/jbc.272.9.5682
   PubMed Web of Science ®Google Scholar
• Sun B, Huang W, Liu M. Evaluation of the combination mode of azoles antifungal inhibitors with CACYP51 and the influence of Site-directed mutation. J Mol Graph Model. 2017;73:157–165. doi:10.1016/j.jmgm.2017.02.009
   PubMed Web of Science ®Google Scholar
• Rosam K, Monk BC, Lackner M. Sterol 14α-demethylase ligand-binding pocket-mediated acquired and intrinsic azole resistance in fungal pathogens. J Fungi. 2021;7(1):1–22. doi:10.3390/jof7010001
   Web of Science ®Google Scholar
• Scouras AD, Daggett V. The dynameomics rotamer library: amino acid side chain conformations and dynamics from comprehensive molecular dynamics simulations in water. Protein Sci. 2011;20(2):341–352. doi:10.1002/pro.565
   PubMed Web of Science ®Google Scholar
• Kufareva I, Abagyan R. Methods of protein structure comparison in homology modeling: methods and protocols. In: Methods of Protein Structure Comparison in Homology Modeling: Methods and Protocols, Methods in Molecular Biology. Vol. 857. Humana Press; 2012:231–257. doi:10.1007/978-1-61779-588-6
   Google Scholar
• Aier I, Varadwaj PK, Raj U. Structural insights into conformational stability of both wild-type and mutant EZH2 receptor. Sci Rep. 2016;6:1–10. doi:10.1038/srep34984
   PubMed Web of Science ®Google Scholar
• Lobanov MI, Bogatyreva NS, Galzitskaia OV. Radius of gyration is indicator of compactness of protein structure. Mol Biol (Mosk). 2008;42(4):701–706.
   PubMed Web of Science ®Google Scholar
• Lobanov MY, Bogatyreva NS, Galzitskaya OV. Radius of gyration as an indicator of protein structure compactness. Mol Biol. 2008;42(4):623–628. doi:10.1134/S0026893308040195
   Web of Science ®Google Scholar
• Tsai CJ, Nussinov R. Hydrophobic folding units at protein-protein interfaces: implications to protein folding and to protein-protein association. Protein Sci. 1997;6(7):1426–1437. doi:10.1002/pro.5560060707
   Web of Science ®Google Scholar
• Gromiha MM. Protein structure prediction. Protein Bioinform. 2010;1986:143–207. doi:10.1016/b978-8-1312-2297-3.50005-9
   Google Scholar
• Fullerton GD, Cameron IL. Water compartments in cells. Methods Enzymol. 2007;428:1–28. doi:10.1016/S0076-6879(07)28001-2
   Web of Science ®Google Scholar
• Hubbard RE, Kamran Haider M. Hydrogen bonds in proteins: role and strength. Encycloped Life Sci. 2010. doi:10.1002/9780470015902.a0003011.pub2
   Google Scholar
• Montes K, Ortiz B, Galindo C, Figueroa I, Braham S, Fontecha G. Identification of Candida species from clinical samples in a Honduran tertiary hospital. Pathogens. 2019;8(4):1–11. doi:10.3390/pathogens8040237
   Web of Science ®Google Scholar
• Khadka S, Sherchand JB, Pokhrel BM, et al. Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal. BMC Res Notes. 2017;10(1):1–5. doi:10.1186/s13104-017-2547-3
   Web of Science ®Google Scholar
• Manikandan C, Amsath A. Characterization and susceptibility pattern of Candida species isolated from urine samples in Pattukkottai, Tamilnadu, India. Int J Pure Appl Zool. 2015;3(1):17–23.
   Google Scholar
• Reddy Edula A. Antifungal susceptibility of clinically significant Candida species by disk diffusion method. IP Int J Med Microbiol Trop Dis. 2021;7(2):77–80. doi:10.18231/j.ijmmtd.2021.017
   Google Scholar
• Swoboda-Kopec E, Kawecki D, Wroblewska M, Krawczyk M, Luczak M. Epidemiology and susceptibility to antifungal agents of fungi isolated from clinical specimens from patients hospitalized in the Department of General and Liver Surgery of the Medical University of Warsaw. Transplant Proc. 2003;35(6):2298–2303. doi:10.1016/S0041-1345(03)00757-7
   Web of Science ®Google Scholar
• Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol. 2007;56(PART2):255–259. doi:10.1099/jmm.0.46817-0
   Web of Science ®Google Scholar
• Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One. 2014;9(7). doi:10.1371/journal.pone.0101510
   Web of Science ®Google Scholar
• Gutiérrez J, Morales P, González MA, Quindós G. Candida dubliniensis, a new fungal pathogen. J Basic Microbiol. 2002;42(3):207–227. doi:10.32388/ef9mql
   Web of Science ®Google Scholar
• Khan Z, Ahmad S, Joseph L, Chandy R. Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen. PLoS One. 2012;7(3):e32952. doi:10.1371/journal.pone.0032952
   Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Gee S, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol. 1999;37(3):870–872. doi:10.1128/jcm.37.3.870-872.1999
   Web of Science ®Google Scholar
• Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2017;7:1–12. doi:10.3389/fmicb.2016.02173
   Web of Science ®Google Scholar
• Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med. 2013;369(9):830–839. doi:10.1056/nejmoa1301066
   PubMed Web of Science ®Google Scholar
• Martin MV. Review The use of fluconazole and itraconazole in the treatment of. J Antimicrob Chemother. 1999;44:429–437. doi:10.1093/jac/44.4.429
   PubMed Web of Science ®Google Scholar
• Pasko MT, Piscitelli SC, Van Slooten AD. Formulary forum. Ann Pharmacother. 1989;24(9):860–867.
   Google Scholar
• Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876–883. doi:10.1056/nejmoa033114
   PubMed Web of Science ®Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004;10(SUPPL. 1):1–10. doi:10.1111/j.1470-9465.2004.00841.x
   PubMed Web of Science ®Google Scholar
• Nielsen LE, Forrester JB, Girotto JE, Dassner AM, Humphries R. One size fits all? Application of susceptible-dose-dependent breakpoints to pediatric patients and laboratory reporting. J Clin Microbiol. 2020;58(1):1–8. doi:10.1128/JCM.01446-19
   Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49(2):668–679. doi:10.1128/AAC.49.2.668-679.2005
   PubMed Web of Science ®Google Scholar
• Teo JQM, Lee SJY, Tan AL, et al. Molecular mechanisms of azole resistance in Candida bloodstream isolates. BMC Infect Dis. 2019;19(1):1–4. doi:10.1186/s12879-019-3672-5
   Web of Science ®Google Scholar
• Yao D, Chen J, Chen W, Li Z, Hu X. Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist. 2019;12:771–781. doi:10.2147/IDR.S202058
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken LB, Hollis RJ, et al. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J Clin Microbiol. 2008;46(11):3585–3590. doi:10.1128/JCM.01391-08
   Web of Science ®Google Scholar
• Espinel-Ingroff A, Canton E, Peman J, Rinaldi MG, Fothergill AW. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 document) in three laboratories: results obtained with 2162 clinical isolates of Candida spp. and other. J Clin Microbiol. 2009;47(9):2766–2771. doi:10.1128/JCM.00654-09
   PubMed Web of Science ®Google Scholar
• Wang JM, Bennett RJ, Andersona MZ. The genome of the human pathogen Candida albicans is shaped by mutation and cryptic sexual recombination. MBio. 2018;9(5):1–16.
   Web of Science ®Google Scholar
• Sitterlé E, Maufrais C, Sertour N, Palayret M, d’Enfert C, Bougnoux ME. Within-host genomic diversity of Candida albicans in healthy carriers. Sci Rep. 2019;9(1):1–12. doi:10.1038/s41598-019-38768-4
   Web of Science ®Google Scholar
• Pryszcz LP, Németh T, Gácser A, Gabaldón T. Unexpected genomic variability in clinical and environmental strains of the pathogenic yeast Candida parapsilosis. Genome Biol Evol. 2013;5(12):2382–2392. doi:10.1093/gbe/evt185
   PubMed Web of Science ®Google Scholar
• Roman EA, Faraj SE, Gallo M, Salvay AG, Ferreiro DU, Santos J. Protein stability and dynamics modulation: the case of human frataxin. PLoS One. 2012;7(9):e45743. doi:10.1371/journal.pone.0045743
   Web of Science ®Google Scholar
• Bahar I, Lezon TR, Yang LW, Eyal E. Global dynamics of proteins: bridging between structure and function. Annu Rev Biophys. 2010;39(1):23–42. doi:10.1146/annurev.biophys.093008.131258
   PubMed Web of Science ®Google Scholar
• Laskowski RA, Gerick F, Thornton JM. The structural basis of allosteric regulation in proteins. FEBS Lett. 2009;583(11):1692–1698. doi:10.1016/j.febslet.2009.03.019
   PubMed Web of Science ®Google Scholar
• Mane A, Vidhate P, Kusro C, et al. Molecular mechanisms associated with Fluconazole resistance in clinical Candida albicans isolates from India. Mycoses. 2016;59(2):93–100. doi:10.1111/myc.12439
   Web of Science ®Google Scholar
• Morschhäuser J. The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen. J Microbiol. 2016;54(3):192–201. doi:10.1007/s12275-016-5628-4
   PubMed Web of Science ®Google Scholar
• Prakash SMU, Nazeer Y, Jayanthi S, Kabir MA. Computational insights into fluconazole resistance by the suspected mutations in lanosterol 14α-demethylase (Erg11p) of Candida albicans. Mol Biol Res Commun. 2020;9(4):155–167. doi:10.22099/mbrc.2020.36298.1476
   Web of Science ®Google Scholar
• Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis. 2010;66(4):373–384. doi:10.1016/j.diagmicrobio.2009.11.006
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Waterman MR. Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all Biological Kingdoms. Biochim Biophys Acta. 2008;1770(3):467–477. doi:10.1016/j.bbagen.2006.07.018
   Web of Science ®Google Scholar
• Lepesheva GI, Waterman MR. Structural basis for conservation in the CYP51 family. Biochimica et Biophysica Acta. 2011;1814(1):88–93. doi:10.1016/j.bbapap.2010.06.006
   PubMed Web of Science ®Google Scholar
• Lepesheva GI, Waterman MR. CYP51 - the omnipotent P450. Mol Cell Endocrinol. 2004;215(1–2):165–170. doi:10.1016/j.mce.2003.11.016
   Web of Science ®Google Scholar
• Lepesheva GI, Virus C, Waterman MR. Conservation in the CYP51 family. Role of the B′ helix/BC loop and helices F and G in enzymatic function. Biochemistry. 2003;42(30):9091–9101. doi:10.1021/bi034663f
   Web of Science ®Google Scholar